SOTIO receives orphan-drug designation for Ovarian Active Cellular Immunotherapy

SOTIO has received orphan-drug designation from the U.S. Food and Drug Administration (FDA) for the active cellular immunotherapy (ACI) DCVAC/OvCa.


SOTIO, LLC becomes a member of Massachusetts Biotechnology Council

SOTIO, LLC officially became a member of Massachusetts Biotechnology Council (MassBio), the largest biotechnology organization in Massachusetts.


SOTIO at ASCO Annual Meeting 2013

At this years annual meeting of the American Society of Clinical Oncology (ASCO) held from May 31 to June 4, in Chicago, Illinois; SOTIO will for the first time ever introduce itself to the worldwide oncology community.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies